Sleep Aids Market by Product (Mattress & Pillows, Sleep Laboratories, Medications, and Sleep Apnea Devices) and Sleep Disorders (Insomnia, Sleep Apnea, Restless Leg Syndrome, Narcolepsy, Sleepwalking, and Other Sleep Disorders): Global Opportunity Analysis and Industry Forecast, 2021–2030
The global sleep aids market was valued at $59,815.10 million in 2020, and is projected to reach $111,920.10 million by 2030, registering a CAGR of 6.9%from 2021 to 2030.
Sleep is a biological requirement that maintains metabolic homeostasis, influences memory and other cognitive functions, and regulates immune function. Sleep aids are drugs, medical devices, and services that are used to diagnose and treat various sleep disorders such as sleep apnea and insomnia. Lack of quality sleep leads to sleep disorders, which are caused due to medical issues, physical disturbances, environmental problems, and psychiatric disorders. These sleep disorders are expected to adversely affect the human health and lead to a number of chronic diseases such as high blood pressure, diabetes, arthritis, and stroke. Thus, it is important to treat and diagnose these disorders at an early stage.
The benefits of using sleep aid products and rise in disposable income drive the growth of the market. Moreover, the rise in the geriatric and obese population has led to an increase in the cases of sleep disorder, which will increase the patient population with sleep disorders also contribute toward the growth of the market. However, the side effects of sleep aid medication on human health and large number of patent expiration of medication are the major barriers for the growth of the market. The advancement of sleep aid product is anticipated to help increase the adoption rate and the untapped market in developing economies are expected to offer lucrative opportunities for market expansion during the forecast period.
The sleep aids market is segmented on the basis of product, sleep disorder, and region. By product, the market is segmented into mattress & pillows, sleep laboratories, medications, and sleep apnea devices. The medications segment is further classified into prescription-based and over-the-counter (OTC) drugs. On the basis of sleep disorders, it is categorized into insomnia, sleep apnea, restless leg syndrome, narcolepsy, sleepwalking, and other sleep disorders. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the sleep aids market is provided.
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By PRODUCT
Mattresses & Pillows
Sleep Laboratories
Medications
Prescription-Based Drugs
OTC Drugs
Sleep Apnea Devices
By SLEEP DISORDERS
Insomnia
Sleep Apnea
Restless Leg Syndrome
Narcolepsy
Sleepwalking
Other Sleep Disorders
By REGION
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia Pacific
Japan
China
Australia
India
South Korea
Rest of Asia Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
KEY MARKET PLAYERS
Cadwell Industries, Inc.
Compumedics Limited
Drive DeVilbiss Healthcare Inc.
GlaxoSmithKline Plc
Merck& Co., Inc.
Natus Medical Inc.
Koninklijke Philips N.V.
PFIZER, INC.
Sanofi S.A.
SleepMed Inc.
- CHAPTER 1:INTRODUCTION
- 1.1.Report Description
- 1.2.Key Market Segments
- 1.3.Key Benefits
- 1.4.Research Methodology
- 1.4.1.Primary Research
- 1.4.2.Secondary Research
- 1.4.3.Analyst Tools and Models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.CXO Perspective
- CHAPTER 3:MARKET LANDSCAPE
- 3.1.Market Definition and Scope
- 3.2.Key Findings
- 3.2.1.Top Investment Pockets
- 3.2.2.Top Winning Strategies
- 3.3.Porter's Five Forces Analysis
- 3.3.1.Bargaining Power of Suppliers
- 3.3.2.Threat of New Entrants
- 3.3.3.Threat of Substitutes
- 3.3.4.Competitive Rivalry
- 3.3.5.Bargaining Power among Buyers
- 3.4.Market Share Analysis Top Player Positioning
- 3.4.1.Market Share Analysis/Top Player Positioning 2020
- 3.5.Market Dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis
- CHAPTER 4:SLEEP AIDS MARKET, BY PRODUCT
- 4.1.Market Overview
- 4.1.1Market Size and Forecast, By Product
- 4.2.MATTRESSES & PILLOWS
- 4.2.1.Key Market Trends, Growth Factors and Opportunities
- 4.2.2.Market Size and Forecast, By Region
- 4.2.3.Market Share Analysis, By Country
- 4.3.SLEEP LABORATORIES
- 4.3.1.Key Market Trends, Growth Factors and Opportunities
- 4.3.2.Market Size and Forecast, By Region
- 4.3.3.Market Share Analysis, By Country
- 4.4.MEDICATIONS
- 4.4.1.Key Market Trends, Growth Factors and Opportunities
- 4.4.2.Market Size and Forecast, By Region
- 4.4.3.Market Share Analysis, By Country
- 4.4.4.Prescription-based drugs
- 4.4.4.1.Market Size and Forecast
- 4.4.5.OTC drugs
- 4.4.5.1.Market Size and Forecast
- 4.5.SLEEP APNEA DEVICES
- 4.5.1.Key Market Trends, Growth Factors and Opportunities
- 4.5.2.Market Size and Forecast, By Region
- 4.5.3.Market Share Analysis, By Country
- CHAPTER 5:SLEEP AIDS MARKET, BY SLEEP DISORDERS
- 5.1.Market Overview
- 5.1.1Market Size and Forecast, By Sleep Disorders
- 5.2.INSOMNIA
- 5.2.1.Market Size and Forecast, By Region
- 5.2.2.Market Share Analysis, By Country
- 5.3.SLEEP APNEA
- 5.3.1.Market Size and Forecast, By Region
- 5.3.2.Market Share Analysis, By Country
- 5.4.RESTLESS LEGS SYNDROME
- 5.4.1.Market Size and Forecast, By Region
- 5.4.2.Market Share Analysis, By Country
- 5.5.NARCOLEPSY
- 5.5.1.Market Size and Forecast, By Region
- 5.5.2.Market Share Analysis, By Country
- 5.6.SLEEPWALKING
- 5.6.1.Market Size and Forecast, By Region
- 5.6.2.Market Share Analysis, By Country
- 5.7.OTHER SLEEP DISORDERS
- 5.7.1.Market Size and Forecast, By Region
- 5.7.2.Market Share Analysis, By Country
- CHAPTER 6:SLEEP AIDS MARKET, BY REGION
- 6.1.Market Overview
- 6.1.1Market Size and Forecast, By Region
- 6.2.North America
- 6.2.1.Key Market Trends and Opportunities
- 6.2.2.Market Size and Forecast, By Product
- 6.2.3.Market Size and Forecast, By Sleep Disorders
- 6.2.4.Market Size and Forecast, By Country
- 6.2.5.United States Sleep Aids Market
- 6.2.5.1.Market Size and Forecast, By Product
- 6.2.5.2.Market Size and Forecast, By Sleep Disorders
- 6.2.6.Canada Sleep Aids Market
- 6.2.6.1.Market Size and Forecast, By Product
- 6.2.6.2.Market Size and Forecast, By Sleep Disorders
- 6.2.7.Mexico Sleep Aids Market
- 6.2.7.1.Market Size and Forecast, By Product
- 6.2.7.2.Market Size and Forecast, By Sleep Disorders
- 6.3.Europe
- 6.3.1.Key Market Trends and Opportunities
- 6.3.2.Market Size and Forecast, By Product
- 6.3.3.Market Size and Forecast, By Sleep Disorders
- 6.3.4.Market Size and Forecast, By Country
- 6.3.5.Germany Sleep Aids Market
- 6.3.5.1.Market Size and Forecast, By Product
- 6.3.5.2.Market Size and Forecast, By Sleep Disorders
- 6.3.6.France Sleep Aids Market
- 6.3.6.1.Market Size and Forecast, By Product
- 6.3.6.2.Market Size and Forecast, By Sleep Disorders
- 6.3.7.Uk Sleep Aids Market
- 6.3.7.1.Market Size and Forecast, By Product
- 6.3.7.2.Market Size and Forecast, By Sleep Disorders
- 6.3.8.Italy Sleep Aids Market
- 6.3.8.1.Market Size and Forecast, By Product
- 6.3.8.2.Market Size and Forecast, By Sleep Disorders
- 6.3.9.Spain Sleep Aids Market
- 6.3.9.1.Market Size and Forecast, By Product
- 6.3.9.2.Market Size and Forecast, By Sleep Disorders
- 6.3.10.Rest Of Europe Sleep Aids Market
- 6.3.10.1.Market Size and Forecast, By Product
- 6.3.10.2.Market Size and Forecast, By Sleep Disorders
- 6.4.Asia-Pacific
- 6.4.1.Key Market Trends and Opportunities
- 6.4.2.Market Size and Forecast, By Product
- 6.4.3.Market Size and Forecast, By Sleep Disorders
- 6.4.4.Market Size and Forecast, By Country
- 6.4.5.Japan Sleep Aids Market
- 6.4.5.1.Market Size and Forecast, By Product
- 6.4.5.2.Market Size and Forecast, By Sleep Disorders
- 6.4.6.China Sleep Aids Market
- 6.4.6.1.Market Size and Forecast, By Product
- 6.4.6.2.Market Size and Forecast, By Sleep Disorders
- 6.4.7.Australia Sleep Aids Market
- 6.4.7.1.Market Size and Forecast, By Product
- 6.4.7.2.Market Size and Forecast, By Sleep Disorders
- 6.4.8.India Sleep Aids Market
- 6.4.8.1.Market Size and Forecast, By Product
- 6.4.8.2.Market Size and Forecast, By Sleep Disorders
- 6.4.9.South Korea Sleep Aids Market
- 6.4.9.1.Market Size and Forecast, By Product
- 6.4.9.2.Market Size and Forecast, By Sleep Disorders
- 6.4.10.Rest Of Asia-pacific Sleep Aids Market
- 6.4.10.1.Market Size and Forecast, By Product
- 6.4.10.2.Market Size and Forecast, By Sleep Disorders
- 6.5.LAMEA
- 6.5.1.Key Market Trends and Opportunities
- 6.5.2.Market Size and Forecast, By Product
- 6.5.3.Market Size and Forecast, By Sleep Disorders
- 6.5.4.Market Size and Forecast, By Country
- 6.5.5.Brazil Sleep Aids Market
- 6.5.5.1.Market Size and Forecast, By Product
- 6.5.5.2.Market Size and Forecast, By Sleep Disorders
- 6.5.6.Saudi Arabia Sleep Aids Market
- 6.5.6.1.Market Size and Forecast, By Product
- 6.5.6.2.Market Size and Forecast, By Sleep Disorders
- 6.5.7.South Africa Sleep Aids Market
- 6.5.7.1.Market Size and Forecast, By Product
- 6.5.7.2.Market Size and Forecast, By Sleep Disorders
- 6.5.8.Rest of LAMEA Sleep Aids Market
- 6.5.8.1.Market Size and Forecast, By Product
- 6.5.8.2.Market Size and Forecast, By Sleep Disorders
- CHAPTER 7:COMPANY PROFILES
- 7.1.Cadwell Industries, Inc.
- 7.1.1.Company Overview
- 7.1.2.Key Executives
- 7.1.3.Company snapshot
- 7.1.4.Operating business segments
- 7.1.5.Product portfolio
- 7.1.6.Business Performance
- 7.1.7.Key Strategic Moves and Developments
- 7.2.Compumedics Limited
- 7.2.1.Company Overview
- 7.2.2.Key Executives
- 7.2.3.Company snapshot
- 7.2.4.Operating business segments
- 7.2.5.Product portfolio
- 7.2.6.Business Performance
- 7.2.7.Key Strategic Moves and Developments
- 7.3.Drive DeVilbiss Healthcare Inc.
- 7.3.1.Company Overview
- 7.3.2.Key Executives
- 7.3.3.Company snapshot
- 7.3.4.Operating business segments
- 7.3.5.Product portfolio
- 7.3.6.Business Performance
- 7.3.7.Key Strategic Moves and Developments
- 7.4.GlaxoSmithKline Plc
- 7.4.1.Company Overview
- 7.4.2.Key Executives
- 7.4.3.Company snapshot
- 7.4.4.Operating business segments
- 7.4.5.Product portfolio
- 7.4.6.Business Performance
- 7.4.7.Key Strategic Moves and Developments
- 7.5.Merck And Co., Inc.
- 7.5.1.Company Overview
- 7.5.2.Key Executives
- 7.5.3.Company snapshot
- 7.5.4.Operating business segments
- 7.5.5.Product portfolio
- 7.5.6.Business Performance
- 7.5.7.Key Strategic Moves and Developments
- 7.6.Natus Medical Inc.
- 7.6.1.Company Overview
- 7.6.2.Key Executives
- 7.6.3.Company snapshot
- 7.6.4.Operating business segments
- 7.6.5.Product portfolio
- 7.6.6.Business Performance
- 7.6.7.Key Strategic Moves and Developments
- 7.7.Koninklijke Philips N.V.
- 7.7.1.Company Overview
- 7.7.2.Key Executives
- 7.7.3.Company snapshot
- 7.7.4.Operating business segments
- 7.7.5.Product portfolio
- 7.7.6.Business Performance
- 7.7.7.Key Strategic Moves and Developments
- 7.8.PFIZER, INC.
- 7.8.1.Company Overview
- 7.8.2.Key Executives
- 7.8.3.Company snapshot
- 7.8.4.Operating business segments
- 7.8.5.Product portfolio
- 7.8.6.Business Performance
- 7.8.7.Key Strategic Moves and Developments
- 7.9.Sanofi S.A.
- 7.9.1.Company Overview
- 7.9.2.Key Executives
- 7.9.3.Company snapshot
- 7.9.4.Operating business segments
- 7.9.5.Product portfolio
- 7.9.6.Business Performance
- 7.9.7.Key Strategic Moves and Developments
- 7.10.SleepMed Inc.
- 7.10.1.Company Overview
- 7.10.2.Key Executives
- 7.10.3.Company snapshot
- 7.10.4.Operating business segments
- 7.10.5.Product portfolio
- 7.10.6.Business Performance
- 7.10.7.Key Strategic Moves and Developments
- LIST OF TABLES
- TABLE 1.GLOBAL SLEEP AIDS MARKET, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 2.GLOBAL SLEEP AIDS MARKET FOR MATTRESSES & PILLOWS, BY REGION, 2020-2030 ($MILLION)
- TABLE 3.GLOBAL SLEEP AIDS MARKET FOR SLEEP LABORATORIES, BY REGION, 2020-2030 ($MILLION)
- TABLE 4.GLOBAL SLEEP AIDS MARKET FOR MEDICATIONS, BY REGION, 2020-2030 ($MILLION)
- TABLE 5.GLOBAL SLEEP AIDS MARKET FOR SLEEP APNEA DEVICES, BY REGION, 2020-2030 ($MILLION)
- TABLE 6.GLOBAL SLEEP AIDS MARKET, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 7.GLOBAL SLEEP AIDS MARKET FOR INSOMNIA, BY REGION, 2020-2030 ($MILLION)
- TABLE 8.GLOBAL SLEEP AIDS MARKET FOR SLEEP APNEA, BY REGION, 2020-2030 ($MILLION)
- TABLE 9.GLOBAL SLEEP AIDS MARKET FOR RESTLESS LEGS SYNDROME, BY REGION, 2020-2030 ($MILLION)
- TABLE 10.GLOBAL SLEEP AIDS MARKET FOR NARCOLEPSY, BY REGION, 2020-2030 ($MILLION)
- TABLE 11.GLOBAL SLEEP AIDS MARKET FOR SLEEPWALKING, BY REGION, 2020-2030 ($MILLION)
- TABLE 12.GLOBAL SLEEP AIDS MARKET FOR OTHER SLEEP DISORDERS, BY REGION, 2020-2030 ($MILLION)
- TABLE 13.GLOBAL SLEEP AIDS MARKET, BY REGION, 2020-2030 ($MILLION)
- TABLE 14.NORTH AMERICA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 15.NORTH AMERICA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 16.UNITED STATES SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 17.UNITED STATES SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 18.CANADA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 19.CANADA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 20.MEXICO SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 21.MEXICO SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 22.EUROPE SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 23.EUROPE SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 24.GERMANY SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 25.GERMANY SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 26.FRANCE SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 27.FRANCE SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 28.UK SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 29.UK SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 30.ITALY SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 31.ITALY SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 32.SPAIN SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 33.SPAIN SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 34.REST OF EUROPE SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 35.REST OF EUROPE SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 36.ASIA-PACIFIC SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 37.ASIA-PACIFIC SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 38.JAPAN SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 39.JAPAN SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 40.CHINA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 41.CHINA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 42.AUSTRALIA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 43.AUSTRALIA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 44.INDIA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 45.INDIA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 46.SOUTH KOREA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 47.SOUTH KOREA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 48.REST OF ASIA-PACIFIC SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 49.REST OF ASIA-PACIFIC SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 50.LAMEA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 51.LAMEA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 52.BRAZIL SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 53.BRAZIL SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 54.SAUDI ARABIA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 55.SAUDI ARABIA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 56.SOUTH AFRICA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 57.SOUTH AFRICA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 58.REST OF LAMEA SLEEP AIDS, BY PRODUCT, 2020-2030 ($MILLION)
- TABLE 59.REST OF LAMEA SLEEP AIDS, BY SLEEP DISORDERS, 2020-2030 ($MILLION)
- TABLE 60.CADWELL INDUSTRIES, INC.: KEY EXECUTIVES
- TABLE 61.CADWELL INDUSTRIES, INC.: COMPANY SNAPSHOT
- TABLE 62.CADWELL INDUSTRIES, INC.: OPERATING SEGMENTS
- TABLE 63.CADWELL INDUSTRIES, INC.: PRODUCT PORTFOLIO
- TABLE 64.CADWELL INDUSTRIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 65.COMPUMEDICS LIMITED: KEY EXECUTIVES
- TABLE 66.COMPUMEDICS LIMITED: COMPANY SNAPSHOT
- TABLE 67.COMPUMEDICS LIMITED: OPERATING SEGMENTS
- TABLE 68.COMPUMEDICS LIMITED: PRODUCT PORTFOLIO
- TABLE 69.COMPUMEDICS LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 70.DRIVE DEVILBISS HEALTHCARE INC.: KEY EXECUTIVES
- TABLE 71.DRIVE DEVILBISS HEALTHCARE INC.: COMPANY SNAPSHOT
- TABLE 72.DRIVE DEVILBISS HEALTHCARE INC.: OPERATING SEGMENTS
- TABLE 73.DRIVE DEVILBISS HEALTHCARE INC.: PRODUCT PORTFOLIO
- TABLE 74.DRIVE DEVILBISS HEALTHCARE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 75.GLAXOSMITHKLINE PLC: KEY EXECUTIVES
- TABLE 76.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
- TABLE 77.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
- TABLE 78.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
- TABLE 79.GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 80.MERCK AND CO., INC.: KEY EXECUTIVES
- TABLE 81.MERCK AND CO., INC.: COMPANY SNAPSHOT
- TABLE 82.MERCK AND CO., INC.: OPERATING SEGMENTS
- TABLE 83.MERCK AND CO., INC.: PRODUCT PORTFOLIO
- TABLE 84.MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 85.NATUS MEDICAL INC.: KEY EXECUTIVES
- TABLE 86.NATUS MEDICAL INC.: COMPANY SNAPSHOT
- TABLE 87.NATUS MEDICAL INC.: OPERATING SEGMENTS
- TABLE 88.NATUS MEDICAL INC.: PRODUCT PORTFOLIO
- TABLE 89.NATUS MEDICAL INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 90.KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
- TABLE 91.KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
- TABLE 92.KONINKLIJKE PHILIPS N.V.: OPERATING SEGMENTS
- TABLE 93.KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
- TABLE 94.KONINKLIJKE PHILIPS N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 95.PFIZER, INC.: KEY EXECUTIVES
- TABLE 96.PFIZER, INC.: COMPANY SNAPSHOT
- TABLE 97.PFIZER, INC.: OPERATING SEGMENTS
- TABLE 98.PFIZER, INC.: PRODUCT PORTFOLIO
- TABLE 99.PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 100.SANOFI S.A.: KEY EXECUTIVES
- TABLE 101.SANOFI S.A.: COMPANY SNAPSHOT
- TABLE 102.SANOFI S.A.: OPERATING SEGMENTS
- TABLE 103.SANOFI S.A.: PRODUCT PORTFOLIO
- TABLE 104.SANOFI S.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 105.SLEEPMED INC.: KEY EXECUTIVES
- TABLE 106.SLEEPMED INC.: COMPANY SNAPSHOT
- TABLE 107.SLEEPMED INC.: OPERATING SEGMENTS
- TABLE 108.SLEEPMED INC.: PRODUCT PORTFOLIO
- TABLE 109.SLEEPMED INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- LIST OF FIGURES
- FIGURE 1.GLOBAL SLEEP AIDS MARKET SEGMENTATION
- FIGURE 2.GLOBAL SLEEP AIDS MARKET
- FIGURE 3.SEGMENTATION SLEEP AIDS MARKET
- FIGURE 4.TOP INVESTMENT POCKET IN SLEEP AIDS MARKET
- FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*
- FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)
- FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
- FIGURE 8.MODERATE BARGAINING POWER OF BUYERS
- FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
- FIGURE 11.LOW THREAT OF SUBSTITUTION
- FIGURE 12.HIGH COMPETITIVE RIVALRY
- FIGURE 13.TOP PLAYER POSITIONING, 2020
- FIGURE 14.MARKET SHARE ANALYSIS, 2020
- FIGURE 15.RESTRAINTS AND DRIVERS: SLEEP AIDS MARKET
- FIGURE 16.SLEEP AIDS MARKET SEGMENTATION, BY PRODUCT
- FIGURE 17.SLEEP AIDS MARKET FOR MATTRESSES & PILLOWS, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 18.SLEEP AIDS MARKET FOR SLEEP LABORATORIES, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 19.SLEEP AIDS MARKET FOR MEDICATIONS, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 20.SLEEP AIDS MARKET FOR SLEEP APNEA DEVICES, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 21.SLEEP AIDS MARKET SEGMENTATION, BY SLEEP DISORDERS
- FIGURE 22.SLEEP AIDS MARKET FOR INSOMNIA, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 23.SLEEP AIDS MARKET FOR SLEEP APNEA, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 24.SLEEP AIDS MARKET FOR RESTLESS LEGS SYNDROME, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 25.SLEEP AIDS MARKET FOR NARCOLEPSY, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 26.SLEEP AIDS MARKET FOR SLEEPWALKING, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 27.SLEEP AIDS MARKET FOR OTHER SLEEP DISORDERS, BY COUNTRY, 2020-2030 ($MILLION)
- FIGURE 28.CADWELL INDUSTRIES, INC.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 29.CADWELL INDUSTRIES, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 30.CADWELL INDUSTRIES, INC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 31.COMPUMEDICS LIMITED: NET SALES, 2018-2020 ($MILLION)
- FIGURE 32.COMPUMEDICS LIMITED: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 33.COMPUMEDICS LIMITED: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 34.DRIVE DEVILBISS HEALTHCARE INC.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 35.DRIVE DEVILBISS HEALTHCARE INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 36.DRIVE DEVILBISS HEALTHCARE INC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 37.GLAXOSMITHKLINE PLC: NET SALES, 2018-2020 ($MILLION)
- FIGURE 38.GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 39.GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 40.MERCK AND CO., INC.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 41.MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 42.MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 43.NATUS MEDICAL INC.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 44.NATUS MEDICAL INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 45.NATUS MEDICAL INC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 46.KONINKLIJKE PHILIPS N.V.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 47.KONINKLIJKE PHILIPS N.V.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 48.KONINKLIJKE PHILIPS N.V.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 49.PFIZER, INC.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 50.PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 51.PFIZER, INC.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 52.SANOFI S.A.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 53.SANOFI S.A.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 54.SANOFI S.A.: REVENUE SHARE, BY REGION, 2020 (%)
- FIGURE 55.SLEEPMED INC.: NET SALES, 2018-2020 ($MILLION)
- FIGURE 56.SLEEPMED INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
- FIGURE 57.SLEEPMED INC.: REVENUE SHARE, BY REGION, 2020 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook